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Stereotactic body radiation therapy
SBRT
T3N0
a b s t r a c t
Objectives: Chest wall invasion (CWI) is observed in 5% of localized non-small cell lung cancer (NSCLC).
The role of stereotactic body radiotherapy (SBRT) in these patients is unknown. We investigate the safety
and efficacy of SBRT in patients with T3N0 NSCLC due to CWI.
Methods: Patients with T3N0 NSCLC due to CWI were identified using a prospective registry. CWI was
defined as radiographic evidence of soft tissue invasion or bony destruction. We excluded patients with
recurrent or metastatic disease. All patients were treated with definitive SBRT. Prescribed dose was 50 Gy
in 5 fractions for most patients. Kaplan-Meier analysis was used to estimate survival outcomes.
Results: We identified 12 patients treated between 2006 and 2017. Median age was 70 (range, 58–85).
Median tumor diameter was 3.0 cm (range, 0.9–7.2). Median survival was 12.0 months (range, 2.4–63).
At a median follow-up of 8.9 months (range, 2.1–63), 1-year primary tumor control was 89%, involved
lobar control was 89%, local–regional control was 82%, distant control was 91%, and survival was 63%.
Of the 4 patients with pre-treatment chest wall pain, 3 reported improvement after SBRT. Two patients
reported new grade 1–2 chest wall pain. No grade 3+ toxicity was reported, with 1 patient experiencing
grade 1 skin toxicity and 3 patients experiencing grade 1–2 radiation pneumonitis.
Conclusions: SBRT for CWI NSCLC is safe, with high early tumor control and low treatment-related toxi-
city. Most patients with pre-treatment chest wall pain experienced relief after SBRT, with no grade 3+
toxicity observed.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer-related death in both the United States and worldwide
[1]. Surgical resection and radiation therapy (RT) are considered
standards of care for patients with early-stage NSCLC. For patients
with medically-inoperable, early-stage disease, stereotactic body
radiotherapy (SBRT) remains standard. Multiple prospective series
have shown SBRT achieves high rates of tumor control with accept-
ably low treatment-related toxicity in both the medically operable
and inoperable settings [2–4]. Of patients with localized NSCLC,
approximately 5% have T3N0 staged disease by evidence of chest
wall invasion (CWI) at diagnosis [5]. While the Radiation Therapy
Oncology Group (RTOG) 0236 trial evaluating SBRT in medically
inoperable early NSCLC did allow patients with T3N0 disease, no
patients with T3N0 disease were enrolled.
With no prospective data to inform us of the role of SBRT in this
select population, questions regarding effectiveness and safety are
still yet to be answered. Of particular importance is chest wall tox-
icity, including skin toxicity, chest wall pain, and rib fractures.
While tumors more than 2 cm from the chest wall or 5 cm from
the posterior skin are at a very low risk, chest wall toxicity is rela-
tively common in tumors of closer proximity [6]. With chest wall
toxicity rates ranging from approximately 5% to 25%, multiple
studies have identified additional factors predictive of developing
chest wall toxicity, with the volume of irradiated chest wall, tumor
size, prescription dose and fractionation all being significant vari-
ables [7–9]. However, T3N0 NSCLC with CWI commonly presents
with pre-treatment chest wall pain and these models did not
include this cohort. The purpose of our study is to identify tumor
control and tolerability of SBRT in the management of patients
with T3N0 NSCLC by virtue of CWI.
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2. Materials and methods
An institutional review board-approved, prospectively-
maintained database in accordance with the Health Insurance
Portability and Accountability Act for patients with newly-
diagnosed, previously untreated stage T3N0 NSCLC with CWI
receiving SBRT with curative intent from 2006 to 2017 was
reviewed. All patients signed an informed consent document for
inclusion in this database prior to treatment. Chest wall invasion
was defined as clinical or radiographic evidence of soft tissue
and/or bony involvement, accordingly T3N0 per American Joint
Committee on Cancer staging, 8th edition [10]. Patients with dis-
tant metastatic disease or recurrent disease at time of SBRT were
excluded from this analysis. Patients with parietal pleural-based
T3N0 lesions without evidence of chest wall soft tissue or bony
destruction were also excluded.
All patients were evaluated by a multidisciplinary team, with
medical inoperability determined by a cardiothoracic surgeon
and/or pulmonologist. Pretreatment evaluation included history
and physical examination as well as pulmonary function tests in
most patients. All patients were staged via computerized tomogra-
phy (CT) of the chest, positron emission tomography (PET), and/or
mediastinal staging with endobronchial ultrasound (EBUS) or
mediastinoscopy for equivocal PET findings. Our institutional SBRT
technique has been described in a previous manuscript [11].
Tumor motion was controlled with abdominal compression to
minimize the range of tumor motion. Patient setup and target ver-
ification was confirmed using daily cone beam CT. Treatment deliv-
ery types included noncoplanar 3-dimensional conformal (3DCRT),
coplanar intensity-modulated radiation therapy (IMRT), and copla-
nar volumetric modulated arc therapy (VMAT). For 3DCRT, pre-
scription was typically to the 75% to 85% isodose line so that 95%
of the prescribed dose covers the PTV. For IMRT/VMAT treatments,
plan optimization was set to recapitulate similar hotspots as the
3DCRT plans. No specific chest wall constraints were utilized in
the treatment planning process, although hotspots are typically
avoided in the chest wall, if possible. For our five-fraction scheme,
normal tissue constraints were respected for the spinal cord (max-
imum dose (Dmax) < 20 Gy), esophagus (Dmax < 30 Gy), heart
(Dmax < 30 Gy), brachial plexus (Dmax < 25 Gy), and the volume
of lung minus internal target volume (ITV) receiving at least
20 Gy (V20Gy) < 10%.
Patients were followed with serial CT scans at 6 weeks’ post-
treatment, then typically every 3 months for 2 years, followed by
every 6 months for an additional 3 years. Survival was calculated
from time of treatment until death or last follow-up. Primary
tumor failure was defined as radiographic evidence of local
enlargement of the treated primary tumor. Hilar and mediastinal
nodal recurrences were included in local–regional failures. The
Kaplan-Meier method was used to estimate control and survival
probabilities and Cox analyses were performed. Significance was
considered at p < 0.05 and all significance levels were 2-sided.
IBM SPSS Statistics, version 23 was applied for all statistical
analyses.
3. Results
3.1. Patients and treatment characteristics
We identified 12 patients who met inclusion and exclusion cri-
teria. Patient, tumor, and treatment-related characteristics are
summarized in Table 1. Median age at diagnosis was 70 years
(range, 58–85). No patients had received prior in-field RT or previ-
ous chemotherapy. Prescription dose was 50 Gy in 5 fractions (bio-
logical effective dose, BED10 = 100 Gy) for all but 3 patients: two
received 54 Gy in 3 fractions (BED10 = 151 Gy) and one other
patient received 62.5 Gy in 10 fractions (BED10 = 102 Gy). Patients
received treatment every other day (10 patients) with the remain-
ing two receiving fractions on consecutive week days. For the 9
patients requiring motion control, abdominal compression was
used in all but 1 patient, who was managed with BodyFix (Bodyfix;
Medical Intelligence, Inc., Quebec, QC, Canada) vacuum restriction
bag. The remaining 3 patients had minimal tumor motion so com-
pression was not used. Delivery was predominantly with non-
coplanar 3DCRT (9 patients), with 2 patients being treated with
coplanar IMRT and 1 other patient with noncoplanar VMAT
(Fig. 1). No patients received adjuvant chemotherapy. Pre-
treatment pulmonary function tests were obtained in 8 patients
(66%). The median FEV1 was 1.3 L and 44% (range, 0.4–2.5 L and
22–72%, respectively), and median DLCO was 46% (range, 33–
69%). Only 2 patients had post-treatment testing, however, with
minimal changes observed in both.
3.2. Outcomes
The median follow-up for all patients was 8.9 months (range,
2.1–62.5 months). The median overall survival was 12.0 months
(2.4–62.8 months). For surviving patients, the estimated 1-year
primary tumor control was 89%, involved lobar control was 89%,
local–regional control was 82%, distant control was 91%, and over-
Table 1
Patient- and treatment-related characteristics (n = 12).
Characteristic Value (% or range)









Smoking pack-years 65 (15–108)
Age-adjusted CCI, median 5 (3–10)
KPS, median 60 (50–80)
Pretreatment hemoglobin (g/dl), mean 12.7 (9.8–15.7)
Histology
Squamous cell carcinoma 6 (50%)
Adenocarcinoma 2 (17%)
NSCLC NOS 2 (17%)
Biopsy unable to be obtained 2 (17%)
Tumor diameter (cm), median 2.7 (0.9–7.2)
PET SUV, median 13.8 (4.4–25.9)
Mediastinal staging




50 Gy in 5 fractions 9 (75%)
54 Gy in 3 fractions 2 (17%)
62.5 Gy in 10 fractions 1 (8%)
Treatment schedule
Consecutive days 2 (17%)
Nonconsecutive days 10 (83%)
Delivery Type
Noncoplanar 3D conformal 9 (75%)
Coplanar IMRT 2 (17%)
Noncoplanar VMAT 1 (8%
PTV volume (cm3), mean 72.2 (10.8–210.6)
BMI, body mass index; CCI, Charlson comorbidity index; KPS, Karnofsky perfor-
mance status, NSCLC NOS, non-small cell lung cancer not otherwise specific; PET
SUV, positron emission tomography standardized uptake value; EBUS, endo-
bronchial ultrasound; IMRT, intensity-modulated radiation therapy; VMAT, volu-
metric modulated arc therapy; PTV, planning target volume
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all survival was 63% (Fig. 2). Table 2 shows the patterns of failure
among study patients. Nodal and distant failures were the most
common sites of treatment failure. No isolated primary tumor fail-
ures were observed. Of the two patients who experienced local fail-
ures, both had either nodal or distant involvement at time of local
failure as well.
Fig. 1. Prescription isodose distributions for a patient treated to 50 Gy in 5 fractions using noncoplanar VMAT.
Fig. 2. Kaplan-Meier curves for local control (a), nodal control (b), distant control (c), and overall survival (d).
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Of the 4 patients who presented with pre-treatment chest wall
pain, 3 (75%) of them reported either improvement or resolution of
their symptoms, with one patient reporting improvement but not
resolution of their symptoms with no further need for narcotic
use, and the other two patients reporting complete resolution of
their symptoms. The other patient reported no change in the
symptoms post-treatment. Of the 8 patients who did not have
pre-treatment chest wall pain, 2 patients developed chest wall
pain requiring over-the-counter medication. The first patient
developed chest wall pain 2 months after SBRT, correlating with
development of pleural-based metastases outside the treatment
field. This patient’s symptoms were improved with over-the-
counter non-steroidal anti-inflammatory (NSAID) medication, and
the patient passed away from metastatic disease before resolution
of their symptoms was documented. The other patient developed
mild rib pain 13 months after treatment that did not require nar-
cotics and resolved with a short course of NSAIDs. No patients
developed treatment-related chest wall pain requiring narcotics
after SBRT and no patients had clinical or radiographic evidence
of rib fractures on follow-up CT imaging. Grade 1 skin toxicity
was observed in 1 patient after treatment which resolved sponta-
neously. Radiation pneumonitis was observed in 3 patients, grade
1 in two cases and only one case of symptomatic grade 2 pneu-
monitis managed with steroids. No grade 3+ pneumonitis or other
toxicity was observed in this cohort.
4. Discussion
We report that SBRT can be safely and effectively delivered in
patients with primary T3N0 NSCLC invading the chest wall. The
frequency of treatment-associated toxicity was low, with no grade
3+ events and symptoms typically being mild and/or self-limited in
the few patients experiencing side effects. Local and lobar control
were high at 89% each in our cohort, although duration of
follow-up was limited, with nodal and distant spread being the
most common patterns of failure in this medically high-risk
patient population. Importantly, in the subset of patients present-
ing with pre-treatment chest wall pain, most patients experienced
relief of their symptoms, indicating that SBRT may be an effective
tool to provide pain relief by virtue of local control.
Historically, patients with lung cancer invading the chest wall
have presented unique challenges to definitive management. The
standard of care for these patients has long been en bloc surgical
resection, often followed by adjuvant chemotherapy. Generally,
acceptable margins are 1 cm in all directions, although some argue
for removing 1 rib above and below the tumor as well as achieving
lateral margins of 3 to 4 cm, given that survival is highly dependent
on completeness of resection [12]. The necessity of complete resec-
tion is balanced by the fact that these are often extensive surgeries
requiring reconstruction of large chest wall defects, although chest
wall defects less than 5 cm can typically be managed without
reconstruction [5]. Even at high-volume centers with skilled tho-
racic surgeons, perioperative mortality is relatively high, with
experiences from Memorial Sloan-Kettering and multi-center
French series reporting mortality rates of up to 8% [13–15]. Sur-
vival after surgical resection varies significantly in the literature
but is generally poor, as 5-year overall survival is approximately
40%, with margin status, extent of invasion, and pathologic nodal
status all significantly influencing this rate [16–18].
Given that surgical resection presents unique, significant chal-
lenges and that many patients are poor operative candidates due
to comorbid cardiopulmonary disease, nonoperative approaches
to management are often necessary. Conventionally-fractionated
radiotherapy has long been described in medically-inoperable
NSCLC, with 2-year disease-free survival only 25% for T3N0
patients treated to doses of at least 60 Gy in 2 Gy fractions [19].
Given historically poor disease control rates with conventionally
fractionated definitive radiotherapy alone for early stage NSCLC
as well as the medical frailty of this demographic, it is unsurprising
that survival at 2- and 5-years has been 35% and 15%, respectively,
in multiple large series [20,21].
Chest wall pain is a common presenting symptom in these
patients, causing significant detriment to quality of life and further
underscoring the importance of local control as an important met-
ric in this cohort. Accordingly, the local control in our series was
89% at 1 year, comparable to reported rates in large SBRT series
of T1-2N0 lesions not invading the chest wall [22,23]. The need
for maximizing local control is balanced with minimizing
treatment-related chest wall toxicity, as large SBRT series have
shown rates of acute and chronic chest wall pain of approximately
5% and 17%, respectively with chest wall V30 and obesity predict-
ing for both pain and skin toxicity [24]. In our subset of patients
that did present with pre-treatment chest wall pain, 75% achieved
pain relief with 50% experiencing complete pain relief. These find-
ings corroborate the Cleveland Clinic experience with treating 10
patients with primary T3N0 NSCLC and an additional 3 patients
with recurrent NSCLC invading the chest wall, which showed pain
relief of 80%, with 50% achieving complete resolution of symptoms
[25]. To our knowledge, there are no other published studies to-
date characterizing outcomes other than the above work by Cleve-
land Clinic and our current series. While two of our patients did
experience new chest wall pain after treatment, both cases were
grade 1–2 with one of these likely due to development of
pleural-based metastases and the other relieved with over-the-
counter medication. We observed no grade 3+ chest wall toxicity,
including no rib fractures, although these events may be observed
over 1-year post-treatment. Furthermore, although post-SBRT pul-
monary function testing was only obtained in 2 of our patients, no
clinically-significant changes from baseline were observed, consis-
tent with other series [26].
Nodal and distant relapse were much more common than local
failures in our series, which is consistent with the greater SBRT
experience for early-stage NSCLC [27]. This observation has led
some to advocate for adjuvant chemotherapy after SBRT, extrapo-
lating from the survival advantage seen in the Cancer and Leuke-
mia Group B (CALGB) 9633 trial for node-negative tumors 4 cm
or greater who had undergone adjuvant chemotherapy after sur-
gery, although none of our patients with larger tumors received
adjuvant systemic therapy [28]. Following a similar logic, multiple
retrospective series have shown improved survival with adjuvant
chemotherapy in surgically-resected pT3N0 NSCLC with chest wall
invasion, independent of size [29–31]. In our series, one third of
patients developed regional nodal metastases as a component of
failure, which might be decreased by systemic therapy. Despite
these observations, the role of adjuvant systemic therapy after
SBRT for NSCLC is still poorly-defined and may warrant prospective
investigation.
Table 2




Local and nodal 1
Local, lobar, nodal and distant 1
Nodal 4
Nodal only 1
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Our study is affected by several limitations inherent to its
design. We investigated a small population of patients with multi-
ple medical comorbidities, with follow-up duration limited by the
high number of intercurrent deaths in the study interval. Conse-
quently, estimates of tumor control are short and further follow-
up with larger sample size may provide more accurate assessment
of these measures. Rates of treatment-related toxicity may be
underestimated by retrospective review, and the addition of
patient-reported quality of life data would further delineate the
analgesic effect of SBRT in this cohort. Furthermore, SBRT tech-
niques have evolved over the study duration at our institution.
Currently, patients are typically treated on consecutive days while
most of the patients in our study were treated when treatment on
nonconsecutive days was routine at our institution, although pre-
vious studies have shown no impact of treatment schedule on out-
come [32]. Furthermore, while most patients on our study were
treated with noncoplanar 3D conformal techniques, we are
increasingly treating patients with VMAT, although its impact on
control and toxicity, if any, are unknown. Despite these limitations,
SBRT appears to be a promising treatment modality for patients
with chest wall-invading tumors.
5. Conclusion
SBRT for patients with NSCLC invading the chest wall appears to
be a feasible, safe, and well-tolerated treatment modality associ-
ated with high rates of early tumor control. For patients experienc-
ing local symptoms, SBRT is effective in providing at least partial
pain relief. For medically-inoperable patients with T3N0 NSCLC
due to CWI, SBRT should be considered as a potential management
option, and warrants further investigation.
Declarations
Ethics approval and consent: Approved by the institutional
review board in accordance with the Health Insurance Portability
and Accountability Act.
Consent for publication: Not applicable.
Availability of data and materials: Please contact author for data
requests
Authors’ contributions:WKwas responsible for study conception
and design, acquisition of data, analysis and interpretation of data,
and drafting of the manuscript. PG was responsible for acquisition
of data, analysis and interpretation of data. JN was responsible for
acquisition of data. CR and JB were responsible for critical revision.
MR was responsible for study conception and design, interpreta-
tion of data, and critical revision.
Funding
Supported by Clinical and Translational Science Award (CTSA)
Grant [UL1 TR000448] and Siteman Comprehensive Cancer Center
and NCI Cancer Center Support Grant P30 CA091842.
Conflict of interest
We have no conflict of interest to disclose for this work.
Acknowledgements
Not applicable.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ctro.2019.02.004.
References
[1] Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol
2016;893:1–19.
[2] Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic
body radiation therapy in medically inoperable stage i non-small cell lung
cancer. JAMA Oncol 2018;4:1287–8.
[3] Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus
lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of
two randomised trials. Lancet Oncol 2015;16:630–7.
[4] Timmerman RD, Paulus R, Pass HI, et al. stereotactic body radiation therapy for
operable early-stage lung cancer: findings from the NRG oncology RTOG 0618
trial. JAMA Oncol 2018;4:1263–6.
[5] Lanuti M. Surgical management of lung cancer involving the chest wall. Thorac
Surg Clin 2017;27:195–9.
[6] Stephans KL, Djemil T, Tendulkar RD, et al. Prediction of chest wall toxicity
from lung stereotactic body radiotherapy (SBRT). Int J Rad Oncol*Biol*Phys
2012;82:974–80.
[7] Dunlap NE, Cai J, Biedermann GB, Wall Chest, et al. Volume receiving >30 Gy
predicts risk of severe pain and/or rib fracture after lung stereotactic body
radiotherapy. Int J Rad Oncol*Biol*Phys 2010;76:796–801.
[8] Mutter RW, Liu F, Abreu A, et al. Dose-volume parameters predict for the
development of chest wall pain after stereotactic body radiation for lung
cancer. Int J Radiat Oncol Biol Phys 2012;82:1783–90.
[9] Woody NM, Videtic GMM, Stephans KL, et al. Predicting chest wall pain from
lung stereotactic body radiotherapy for different fractionation schemes. Int J
Rad Oncol*Biol*Phys 2012;83:427–34.
[10] Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC lung cancer staging
project: the new database to inform the eighth edition of the TNM
classification of lung cancer. J Thorac Oncol 2014;9:1618–24.
[11] Bradley JD, El Naqa I, Drzymala RE, et al. Stereotactic body radiation therapy
for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J
Rad Oncol*Biol*Phys 2010;77:1146–50.
[12] Facciolo F, Cardillo G, Lopergolo M, et al. Chest wall invasion in non–small cell
lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg
2001;121:649–56.
[13] Downey RJ, Martini N, Rusch VW, et al. Extent of chest wall invasion and
survival in patients with lung cancer. Ann Thorac Surg 1999;68:188–93.
[14] Magdeleinat P, Alifano M, Benbrahem C, et al. Surgical treatment of lung
cancer invading the chest wall: results and prognostic factors. Ann Thorac Surg
2001;71:1094–9.
[15] Doddoli C, D’Journo B, Pimpec-Barthes FL, et al. Lung cancer invading the chest
wall: a plea for en-bloc resection but the need for new treatment strategies.
Ann Thorac Surg 2005;80:2032–40.
[16] Chapelier A, Fadel E, Macchiarini P, et al. Factors affecting long-term survival
after en-bloc resection of lung cancer invading the chest wall. Eur J
Cardiothorac Surg 2000;18:513–8.
[17] Voltolini L, Rapicetta C, Luzzi L, et al. Lung cancer with chest wall involvement:
predictive factors of long-term survival after surgical resection. Lung Cancer
2006;52:359–64.
[18] Piehler JM, Pairolero PC, Weiland LH, et al. Bronchogenic carcinoma with chest
wall invasion: factors affecting survival following en bloc resection. Ann
Thorac Surg 1982;34:684–91.
[19] Dosoretz DE, Katin MJ, Blitzer PH, et al. Radiation therapy in the
management of medically inoperable carcinoma of the lung: results and
implications for future treatment strategies. Int J Radiat Oncol Biol Phys
1992;24:3–9.
[20] Graham PH, Gebski VJ, Stat M, et al. Radical radiotherapy for early nonsmall
cell lung cancer. Int J Rad Oncol*Biol*Phys 1995;31:261–6.
[21] Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically
inoperable stage I non-small–cell lung cancer: the duke experience. Int J Rad
Oncol*Biol*Phys 1998;40:149–54.
[22] Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy
(HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257
patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:
S94–100.
[23] Murray P, Franks K, Hanna GG. A systematic review of outcomes following
stereotactic ablative radiotherapy in the treatment of early-stage primary lung
cancer. Br J Radiol 2017;90.
[24] Welsh J, Thomas J, Shah D, et al. Obesity increases the risk of chest wall pain
from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys
2011;81:91–6.
[25] Berriochoa C, Videtic GMM, Woody NM, et al. Stereotactic body radiotherapy
for T3N0 lung cancer with chest wall invasion. Clin Lung Cancer
2016;17:595–601.
W.R. Kennedy et al. / Clinical and Translational Radiation Oncology 16 (2019) 1–6 5
[26] Stanic S, Paulus R, Timmerman RD, et al. No clinically significant changes in
pulmonary function following stereotactic body radiation therapy for early-
stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J
Radiat Oncol Biol Phys 2014;88:1092–9.
[27] Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure
following stereotactic body radiation therapy in early-stage non-small-cell
lung cancer: Clinical implications. Radiother Oncol 2010;94:1–11.
[28] Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus
carboplatin compared with observation in stage IB non-small-cell lung
cancer: CALGB 9633 with the cancer and leukemia group B, radiation
therapy oncology group, and north central cancer treatment group study
groups. JCO 2008;26:5043–51.
[29] Ahmad U, Crabtree TD, Patel AP, et al. Adjuvant chemotherapy is associated
with improved survival in locally invasive node negative non-small cell lung
cancer. Ann Thorac Surg 2017;104:303–7.
[30] Gao SJ, Corso CD, Blasberg JD, et al. Role of adjuvant therapy for node-
negative lung cancer invading the chest wall. Clin Lung Cancer 2017;
18(169–177):e4.
[31] Drake JA, Sullivan JL, Weksler B. Adjuvant chemotherapy improves survival in
patients with completely resected T3N0 non–small cell lung cancer invading
the chest wall. J Thorac Cardiovasc Surg 2018;155:1794–802.
[32] Samson P, Rehman S, Juloori A, et al. Local control for clinical stage I non-small
cell lung cancer treated with 5-fraction stereotactic body radiation therapy is
not associated with treatment schedule. Pract Rad Oncol 2018.
6 W.R. Kennedy et al. / Clinical and Translational Radiation Oncology 16 (2019) 1–6
